Skip to content

Prof. dr. Arnon Kater

Arnon Kater

Department of Hermatology AmsterdamUMC.

After my PhD I set up a research group that performs both pre-clinical and translational studies with focus on (immune)biology and treatment of B-cell malignancies with CLL as main disease serving as a B-cell malignancy model. These studies were combined with both phase 1, 2 and 3 clinical trials for which he started an international network. These efforts have positioned the research group as the foremost clinical and translational CLL Center in the Netherlands and enabled me to build a large countrywide CLL biobank. In this area, main interests are: (resistance to) targeted therapies and cellular therapies.

5 recent publications related to B-cells and antibodies

  1. Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol. 2020 Oct 8;10:592205. doi: 10.3389/fonc.2020.592205. PMID: 33134182; PMCID: PMC7578574.
  2. Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 Sep 28:JCO2000948. doi: 10.1200/JCO.20.00948. Epub ahead of print. PMID: 32986498.
  3. Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E. Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020 Jun 30:blood.2019004326. doi: 10.1182/blood.2019004326. Epub ahead of print. PMID: 32603412.
  4. Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater AP. Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 2020 Oct 7:blood.2020008608. doi: 10.1182/blood.2020008608. Epub ahead of print. PMID: 33027809.
  5. Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie- Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica. 2020 Jan 23:haematol.2019.239947. doi: 10.3324/haematol.2019.239947. Epub ahead of print. PMID: 31974198

Supervision of PhD awarded candidates

  1. Dr Sanne Tonino
  2. Rachel Thijssen,
  3. Martijn van Attekum,
  4. Doreen te Raa
  5. Iris de Weerdt
  6. Tom Hofland
  7. Alexander Leeksma

Currently supervision PhD research of 10 PhD students.

Work package leader WP7.

Back To Top